Close Menu

thyroid cancer

NEW YORK (GenomeWeb News) – Molecular cytology firm Veracyte has filed for an initial public offering in the US.
The South San Francisco, Calif.-based firm was founded in 2006 as Calderome, but changed its name to Veracyte in early 2008.

NEW YORK (GenomeWeb News) – Investigators at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J.

NEW YORK (GenomeWeb News) – Veracyte announced today that Aetna will provide its members with coverage for the firm's Afirma Gene Expression Classifier, a genomic test used to clarify results as benign or suspicious for cancer.

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Veracyte today announced the final tranche of its Series C financing round raising $28 million.

NEW YORK (GenomeWeb News) – In a special issue of the Journal of the American Medical Association out today, researchers presented a set of studies, editorials, and viewpoint articles centered on a genomics theme.

NEW YORK (GenomeWeb News) – Veracyte today announced that private payor UnitedHealthcare has issued a positive medical coverage policy for the firm's molecular diagnostic test for thyroid cancer.

With Positive Survival Data, Genentech Crossing over EMILIA Patients on Lapatinib/Capecitabine Combo to T-DM1

NEW YORK (GenomeWeb News) – Veracyte and Genyzme today announced that the New York State Department of Health has cleared the way for Veracyte's molecular diagnostic test for inconclusive thyroid nodule results to be offered to patients in the state.

Results from a multi-center prospective validation study have confirmed the sensitivity and high negative predictive value of a gene expression test marketed by Veracyte to identify patients whose thyroid nodules are likely to be benign and who can thus avoid further diagnostic s

Quest Diagnostics considers mass spec-based protein tests an "extremely important area" for the company to pursue, Richard Reitz, medical director and chair of the Endocrine Division at Quest's Nichols Institute, told ProteoMonitor in an interview this week.

Pages

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.